Menu
Not yet recruiting NCT07192484

Effects of Kinesio Taping in Subacute Stroke Patients

No phase Interventional Stroke Gait Rehabilitation

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: KT group, Conventional group.
Who it may be relevant to
Registry conditions: Stroke Gait Rehabilitation. Basic parameters: 20 years — 80 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Center list to be confirmed — check the primary protocol.
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Effects of Kinesio Taping on Gait Ability, Balance, and Neuromuscular Functions in Subacute Stroke Patients With Foot Drop

Overview

A study was designed to investigate the effects of KT on gait ability, balance, and neuromuscular functions in subacute stroke patients with foot drop. The study aims to evaluate the immediate and short-term effects of KT on gait ability, balance, and neuromuscular function in subacute stroke patients with foot drop. A total of 60 participants will be recruited and randomly assigned to either a control group (conventional physical therapy) or an experimental group (receiving additional KT). Both groups will receive 30 minutes of daily physical therapy. The experimental group will undergo an initial assessment before KT application, which includes (1) activation of the dorsiflexor muscles, (2) reduction of plantar flexor spasticity, and (3) stabilization of the ankle in an everted position. After taping, a second assessment will be conducted immediately, and the tape will stay applied to patient's limb for two days, followed by a third assessment. The control group will be assessed only before the intervention and after two days. Primary outcome measures include gait ability (10-meter walk test, laboratory gait parameters, and joint angles and electromyographic activity during walking). Secondary outcomes include balance (Functional reach test, Timed Up and Go test, and Activities-specific Balance Confidence Scale) and neuromuscular function assessments (muscle strength, joint range of motion, spasticity, and proprioception). This project aims to establish and validate a clinically applicable and effective KT protocol as an adjunctive gait training method for subacute stroke patients with foot drop. By enhancing independent and safe walking, this intervention may facilitate the early return to normal daily activities for stroke survivors.

Interventions

  • Behavioral KT group
    Receiving additional KT
  • Behavioral Conventional group
    Conventional physical therapy

Primary outcome measures

  • Gait ability - 10 meter walk test [Time frame: 1. Baseline (prior to KT application, Day 1) 2. Immediately after KT application (Day 1) 3. 48 hours after KT application (Day 3)]
  • Gait ability - Speed (m/s) [Time frame: 1. Baseline (prior to KT application, Day 1) 2. Immediately after KT application (Day 1) 3. 48 hours after KT application (Day 3)]
  • Gait ability - Cadence (steps/minute) [Time frame: 1. Baseline (prior to KT application, Day 1) 2. Immediately after KT application (Day 1) 3. 48 hours after KT application (Day 3)]
  • Gait ability - Stride length (m) [Time frame: 1. Baseline (prior to KT application, Day 1) 2. Immediately after KT application (Day 1) 3. 48 hours after KT application (Day 3)]
  • Gait ability - Step length (m) [Time frame: 1. Baseline (prior to KT application, Day 1) 2. Immediately after KT application (Day 1) 3. 48 hours after KT application (Day 3)]
  • Gait ability - Percentages of stance phase (%) [Time frame: 1. Baseline (prior to KT application, Day 1) 2. Immediately after KT application (Day 1) 3. 48 hours after KT application (Day 3)]
  • Gait ability - Percentages of swing phase (%) [Time frame: 1. Baseline (prior to KT application, Day 1) 2. Immediately after KT application (Day 1) 3. 48 hours after KT application (Day 3)]
  • Gait ability - Gait symmetry (%) [Time frame: 1. Baseline (prior to KT application, Day 1) 2. Immediately after KT application (Day 1) 3. 48 hours after KT application (Day 3)]
  • Gait ability - first maximum toe clearance (cm) [Time frame: 1. Baseline (prior to KT application, Day 1) 2. Immediately after KT application (Day 1) 3. 48 hours after KT application (Day 3)]
  • Gait ability - second maximum toe clearance (cm) [Time frame: 1. Baseline (prior to KT application, Day 1) 2. Immediately after KT application (Day 1) 3. 48 hours after KT application (Day 3)]
Secondary outcome measures (7)
  • Functional reach test [Time frame: 1. Baseline (prior to KT application, Day 1) 2. Immediately after KT application (Day 1) 3. 48 hours after KT application (Day 3)]
  • Timed Up and Go test [Time frame: 1. Baseline (prior to KT application, Day 1) 2. Immediately after KT application (Day 1) 3. 48 hours after KT application (Day 3)]
  • Activities-specific Balance Confidence Scale [Time frame: 1. Baseline (prior to KT application, Day 1) 2. Immediately after KT application (Day 1) 3. 48 hours after KT application (Day 3)]
  • Muscle strength [Time frame: 1. Baseline (prior to KT application, Day 1) 2. Immediately after KT application (Day 1) 3. 48 hours after KT application (Day 3)]
  • Joint range of motion [Time frame: 1. Baseline (prior to KT application, Day 1) 2. Immediately after KT application (Day 1) 3. 48 hours after KT application (Day 3)]
  • Spasticity [Time frame: 1. Baseline (prior to KT application, Day 1) 2. Immediately after KT application (Day 1) 3. 48 hours after KT application (Day 3)]
  • Proprioception [Time frame: 1. Baseline (prior to KT application, Day 1) 2. Immediately after KT application (Day 1) 3. 48 hours after KT application (Day 3)]

Eligibility criteria

Inclusion criteria

  • Age between 20 and 80 years;
  • First unilateral stroke;
  • Stroke onset between at least 1 week and 1 year;
  • Ability to continuously walk 10 meters with or without assistive devices;
  • Presence of foot drop on the affected side during the swing phase due to insufficient ankle dorsiflexion;
  • Brunnstrom stage of the affected lower limb ≥ 3;
  • Presence of mild spasticity in the affected ankle plantar flexors, with a Modified Ashworth Scale score ≤ 2;
  • Ability to follow simple commands

Exclusion criteria

  • Other neurological disorders or unstable medical conditions;
  • Skin allergies that interfere with the use of tape;
  • Visual field defects;
  • Cognitive impairment, defined as a Mini-Mental State Examination (MMSE) score < 24;
  • Pusher syndrome;
  • Ankle contracture;
  • Hemispatial neglect;
  • Poorly controlled hypertension or cardiovascular disease;
  • Any other disease, apart from stroke, that may affect balance or gait.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Single blind
Primary purpose
Treatment

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT07192484 · KSVGH25-CT6-22

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗